Skip to main content
. 2016 Aug 17;2(4):222–232. doi: 10.1016/j.trci.2016.07.001

Table 4.

Percent of trials with specific biomarkers included (this calculation is based on the number of trials in which the inclusion of biomarkers is described)

Biomarker % of trials
Phase III Phase II
1. CSF amyloid 27.7 25
2. CSF tau 22.2 21.1
3. FDG-PET 19.4 11.5
4. vMRI 25 15.3
5. Plasma amyloid 8.3 5.7
6. Plasma tau 0 3.8
7. Amyloid PET 22.2 9.6
8. Tau PET 2.7 0